Biosimilars for the treatment of psoriatic arthritis

References

• So A, Inman RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32:453–471.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Biosimilars in EU. Information guide for healthcare professionals; 2017 Apr 27 [cited 2019 Jun 15]. Available from: www.ema.europa.eu/docs/en_GB/…/05/WC500226648.pdf
   Google Scholar
• US Food and Drug Administration. Biosimilars [cited 2019 June 15].
   Google Scholar
• Jacobs I, Petersel D, Isakov L, et al. Biosimilars for the treatment of chronic inflammatory diseases: a systematic review of published evidence. BioDrugs. 2016;30:525–570.
   PubMed Web of Science ®Google Scholar
• Rath PD, Chen DY, Gu J, et al. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: perspective from the Asia Pacific region. Int J Rheum Dis. 2019;22:9–24.
   PubMed Web of Science ®Google Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679–1687.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093–1102.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an Adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70:40–48.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77:914–921.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179:623–631.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Glover J, Matsunaga N, et al. Efficacy, safety and immunogenicity in randomized, Double-Blind (DB) and Open-Label Extension (OLE) studies comparing FKB327, an Adalimumab biosimilar, with the Adalimumab reference product (Humira®; RP) in patients (pts) with active Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 2799.
   Google Scholar
• European Medicine Agency (EMA). Idacio (EMEA/H/C/004475); 2019 Apr 2 [cited 2019 Jun 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/idacio#authorisation-details-section
   Google Scholar
• Hercogová J, Papp KA, Chyrok V, et al. AURIEL-PsO: a randomised, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB110222 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2019 Jun 17. [Epub ahead of print]. DOI:10.1111/bjd.18220
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51–57.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovský J, Sylwestrzak A, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2017;56:2093–2101.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017 Aug 9:pii: annrheumdis-2017-211591. [Epub ahead of print]. DOI:10.1136/annrheumdis-2017-211591
   Web of Science ®Google Scholar
• Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–938.
   PubMed Web of Science ®Google Scholar
• Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21:130.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT. PF-06438179/GP1111: an infliximab biosimilar. BioDrugs. 2018;32:639–642.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20:155.
   PubMed Web of Science ®Google Scholar
• Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58–64.
   PubMed Web of Science ®Google Scholar
• Magro F, Coelho R, Peixoto A. Can we extrapolate data from one immune-mediated inflammatory disease to another one? Curr Med Chem. 2019;26:248–258.
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Editorial: the American college of rheumatology white paper on biosimilars: it isn’t all white-there is some gray and black. Arthritis Rheumatol. 2018;70:323–325.
   PubMed Web of Science ®Google Scholar
• Blandizzi C, Meroni PL, Lapadula G. Comparing originator biologics and biosimilars: a review of the relevant issues. Clin Ther. 2017;39:1026–1039.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 10;389:2304–2316.
   PubMed Web of Science ®Google Scholar
• Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699–1707.
   PubMed Web of Science ®Google Scholar
• Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to Adalimumab. BioDrugs. 2016;30:339–351.
   PubMed Web of Science ®Google Scholar
• Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76:526–533.
   PubMed Web of Science ®Google Scholar
• Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to Adalimumab. BioDrugs. 2016;30:321–338.
   PubMed Web of Science ®Google Scholar
• Frampton JE. SB5: an Adalimumab biosimilar. BioDrugs. 2018;32:507–510.
   PubMed Web of Science ®Google Scholar
• Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25:1361–1370.
   PubMed Web of Science ®Google Scholar
• von Richter O, Lemke L, Haliduola H, et al. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opin Biol Ther. 2019;30:1–9.
   Google Scholar
• Kronthaler U, Fritsch C, Hainzl O, et al. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opin Biol Ther. 2018;18:921–930.
   PubMed Web of Science ®Google Scholar
• Puri A, Niewiarowski A, Arai Y, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects. Br J Clin Pharmacol. 2017;83:1405–1415.
   PubMed Web of Science ®Google Scholar
• Hyland E, Mant T, Vlachos P, et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects. Br J Clin Pharmacol. 2016;82:983–993.
   PubMed Web of Science ®Google Scholar
• Cantini F, Benucci M. Focus on biosimilar etanercept - bioequivalence and interchangeability. Biologics. 2018;12:87–95.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: inflectra (infliximab); 2013. [cited 2017 Mar 14; cited 2019 June 15] 2017 Mar 14. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf
   Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   PubMed Web of Science ®Google Scholar
• Palaparthy R, Udata C, Hua SY, et al. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01). Expert Rev Clin Immunol. 2018;14:329–336.
   PubMed Web of Science ®Google Scholar
• Shin D, Kim Y, Kim YS, et al. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade(®)) in healthy subjects. BioDrugs. 2015;29:381–388.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Psoriatic arthritis: a systematic review. Int J Rheum Dis. 2010;13:300–317.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Cassarà E, et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis. 2012;15:414–418.
   PubMed Web of Science ®Google Scholar
• Moltó A, Dougados M. Comorbidities in spondyloarthritis including psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32:390–400.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–970.
   PubMed Web of Science ®Google Scholar
• Mok CC, Kwok CL, Ho LY, et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63:1182–1189.
   PubMed Web of Science ®Google Scholar
• Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32:369–389.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Cantini F, Costanzo A, et al. Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev. 2015;14:864–874.
   PubMed Web of Science ®Google Scholar
• Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019;6:23–32.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), patient global for psoriatic arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64–85.
   PubMed Web of Science ®Google Scholar
• Chandran V, Maharaj AB. Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy. Expert Rev Clin Immunol. 2016;12:573–582.
   PubMed Web of Science ®Google Scholar
• Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212–1217.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Ciapetti A, Carotti M, et al. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.
   PubMed Web of Science ®Google Scholar
• Lubrano E, De Socio A, Perrotta FM. Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort. J Rheumatol. 2017;44:1159–1164.
   PubMed Web of Science ®Google Scholar
• Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology (Oxford). 2019:pii: kez215. [Epub ahead of print]. DOI:10.1093/rheumatology/kez215
   PubMedGoogle Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236. Erratum in: Arthritis Rheum 2005; 52: 2951.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Alvarez Martinez D, Solomon JA, et al. Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review. J Rheumatol. 2014;41:2301–2305.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040–1050. Erratum in: J Rheumatol 2007; 34: 1439.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Sampalis JS, Illouz O, et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010;37:1898–1906.
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol. 2009;1:163–178.
   PubMedGoogle Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524.
   PubMed Web of Science ®Google Scholar
• Palazzi C, D’Angelo S, Leccese P, et al. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update. Expert Opin Drug Saf. 2014;13:191–196.
   PubMed Web of Science ®Google Scholar
• Lemos LL, de Oliveira Costa J, Almeida AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014;34:1345–1360.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. FExpert Opin Drug Saf. 2016;15(supp1):11–34.
   PubMedGoogle Scholar
• Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(supp1):35–54.
   PubMedGoogle Scholar
• Dressler C, Eisert L, Pham PA, et al. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol. 2019;33:1249–1260.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014 May;91:47–55.
   PubMedGoogle Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018 Jun;24(Suppl 2):S10–S20.
   PubMed Web of Science ®Google Scholar
• Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653–669.
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85:561–567.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van Den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70:60–68.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426–1431.
   PubMed Web of Science ®Google Scholar
• Giunta A, Manfreda V, Esposito M, et al. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study. Br J Dermatol. 2019 May 3. [Epub ahead of print]. DOI:10.1111/bjd.18090
   Web of Science ®Google Scholar
• Bonifati C, De Felice C, Lora V, et al. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study. J Dermatolog Treat. 2019;15:1–5.
   Google Scholar
• Pescitelli L, Lazzeri L, Di Cesare A, et al. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients. Int J Clin Pharm. 2019;41:9–12.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, Huiskes VJB, van Den Bemt BJF, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort. Study Arthritis Rheumatol. 2018;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78:192–200.
   PubMed Web of Science ®Google Scholar
• Bellinvia S, Cummings JRF, Ardern-Jones MR, et al. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33:241–253.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49:31–40.
   PubMed Web of Science ®Google Scholar
• Cohen S, Pablos JL, Pavelka K, et al. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21:84.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Selmi C, Becciolini A, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res (Hoboken). 2017;69:867–874.
   PubMed Web of Science ®Google Scholar
• Cantini F, Benucci M. Response to: ‘Seeing the glass either half full or half empty: response to the correspondence ‘switching from the bio-originators to biosimilar: is it premature to recommend this procedure?” By Scherlinger and Schaeverbeke. Ann Rheum Dis. 2019;78:e25.
   Google Scholar
• Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? Aaps J. 2014;16:22–26.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. 2015;33:1–4.
   PubMed Web of Science ®Google Scholar
• Araújo FC, Sepriano A, Teixeira F, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update. Acta Reumatol Port. 2017;42:219–228.
   PubMed Web of Science ®Google Scholar
• Abad Hernández MÁ, Andreu JL, Balsa Criado A, et al. Update of the position paper of the Spanish society of rheumatology on biosimilar drugs. Reumatol Clin. 2019:pii: S1699-258X(19)30059–2. [Epub ahead of print]. DOI:10.1016/j.reuma.2019.03.007
   Google Scholar
• Kowalski SC, Benavides JA, Beltrán PA, et al. PANLAR consensus statement on biosimilars. Clin Rheumatol. 2019;38:1485–1496.
   PubMed Web of Science ®Google Scholar
• Bridges SL Jr, White DW, Worthing AB, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018;70:334–344.
   PubMed Web of Science ®Google Scholar